Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
136.38
-1.36 (-0.99%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Employees
Ascendis Pharma had 879 employees as of December 31, 2023. The number of employees increased by 82 or 10.29% compared to the previous year.
Employees
879
Change (1Y)
82
Growth (1Y)
10.29%
Revenue / Employee
$415,458
Profits / Employee
-$541,158
Market Cap
8.15B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
The Ensign Group | 35,300 |
Chemed | 15,087 |
Teleflex | 14,500 |
HealthEquity | 3,150 |
Jazz Pharmaceuticals | 2,800 |
Repligen | 1,783 |
Roivant Sciences | 908 |
ASND News
- 2 days ago - YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults - GlobeNewsWire
- 5 days ago - New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 - GlobeNewsWire
- 9 days ago - FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 11 days ago - Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets - GlobeNewsWire
- 5 weeks ago - Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Ascendis Pharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 2 months ago - New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 - GlobeNewsWire